These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32887995)

  • 1. Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer.
    Smart E; Semina SE; Frasor J
    Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32887995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy.
    Kastrati I; Siklos MI; Brovkovych SD; Thatcher GRJ; Frasor J
    Horm Cancer; 2017 Jun; 8(3):135-142. PubMed ID: 28396978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms.
    Frasor J; El-Shennawy L; Stender JD; Kastrati I
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3(0 3):235-9. PubMed ID: 25450861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
    Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
    BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHLDA1 expression is controlled by an estrogen receptor-NFκB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres.
    Kastrati I; Canestrari E; Frasor J
    Oncogene; 2015 Apr; 34(18):2309-16. PubMed ID: 24954507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective pressure of endocrine therapy activates the integrated stress response through NFκB signaling in a subpopulation of ER positive breast cancer cells.
    Semina SE; Pal P; Kansara NS; Huggins RJ; Alarid ET; Greene GL; Frasor J
    Breast Cancer Res; 2022 Mar; 24(1):19. PubMed ID: 35264224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interaction between ER and NFκB in resistance to endocrine therapy.
    Sas L; Lardon F; Vermeulen PB; Hauspy J; Van Dam P; Pauwels P; Dirix LY; Van Laere SJ
    Breast Cancer Res; 2012 Aug; 14(4):212. PubMed ID: 22963717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements.
    Pradhan M; Bembinster LA; Baumgarten SC; Frasor J
    J Biol Chem; 2010 Oct; 285(41):31100-6. PubMed ID: 20705611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.
    Baumgarten SC; Frasor J
    Mol Endocrinol; 2012 Mar; 26(3):360-71. PubMed ID: 22301780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
    Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
    Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer.
    Toska E
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189097. PubMed ID: 38518961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein.
    Kastrati I; Siklos MI; Calderon-Gierszal EL; El-Shennawy L; Georgieva G; Thayer EN; Thatcher GR; Frasor J
    J Biol Chem; 2016 Feb; 291(7):3639-47. PubMed ID: 26683377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
    Bergamaschi A; Christensen BL; Katzenellenbogen BS
    Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.
    Zhou Y; Eppenberger-Castori S; Marx C; Yau C; Scott GK; Eppenberger U; Benz CC
    Int J Biochem Cell Biol; 2005 May; 37(5):1130-44. PubMed ID: 15743683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coactivation of Estrogen Receptor and IKKβ Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer.
    El-Shennawy L; Dubrovskyi O; Kastrati I; Danes JM; Zhang Y; Whiteley HE; Creighton CJ; Frasor J
    Cancer Res; 2018 Feb; 78(4):974-984. PubMed ID: 29229606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
    Chen AC; Migliaccio I; Rimawi M; Lopez-Tarruella S; Creighton CJ; Massarweh S; Huang C; Wang YC; Batra SK; Gutierrez MC; Osborne CK; Schiff R
    Breast Cancer Res Treat; 2012 Jul; 134(2):583-93. PubMed ID: 22644656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.
    Nakshatri H; Bhat-Nakshatri P; Martin DA; Goulet RJ; Sledge GW
    Mol Cell Biol; 1997 Jul; 17(7):3629-39. PubMed ID: 9199297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
    Santiago-Gómez A; Kedward T; Simões BM; Dragoni I; NicAmhlaoibh R; Trivier E; Sabin V; Gee JM; Sims AH; Howell SJ; Clarke RB
    Cancer Lett; 2019 Aug; 458():66-75. PubMed ID: 31121213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
    Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
    Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.